Analysts expect that Abeona Therapeutics Inc (NASDAQ:ABEO) will announce $270,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Abeona Therapeutics’ earnings, with estimates ranging from $200,000.00 to $400,000.00. Abeona Therapeutics posted sales of $190,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 42.1%. The business is scheduled to issue its next quarterly earnings results on Monday, May 21st.
According to Zacks, analysts expect that Abeona Therapeutics will report full year sales of $270,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $1.40 million. For the next financial year, analysts forecast that the company will post sales of $17.66 million per share, with estimates ranging from $730,000.00 to $38.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.24 million. Abeona Therapeutics had a negative net margin of 3,263.92% and a negative return on equity of 24.57%. The firm’s revenue for the quarter was down 16.0% on a year-over-year basis.
Several research firms have recently weighed in on ABEO. Maxim Group reaffirmed a “buy” rating and set a $35.00 target price on shares of Abeona Therapeutics in a report on Wednesday, February 7th. HC Wainwright set a $30.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday, February 8th. Cantor Fitzgerald set a $36.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Tuesday, March 20th. ValuEngine raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, BidaskClub raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Abeona Therapeutics currently has an average rating of “Buy” and a consensus target price of $28.88.
Shares of NASDAQ:ABEO traded down $0.35 during trading on Tuesday, hitting $14.00. 587,572 shares of the stock traded hands, compared to its average volume of 810,123. The firm has a market cap of $661.18, a price-to-earnings ratio of -21.21 and a beta of 1.29. Abeona Therapeutics has a 52-week low of $4.55 and a 52-week high of $22.75.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas purchased a new stake in Abeona Therapeutics in the 4th quarter worth $163,000. MetLife Investment Advisors LLC purchased a new stake in Abeona Therapeutics in the 4th quarter worth $194,000. SG Americas Securities LLC purchased a new stake in Abeona Therapeutics in the 4th quarter worth $218,000. Virtu Financial LLC purchased a new stake in Abeona Therapeutics in the 4th quarter worth $246,000. Finally, Virtus Fund Advisers LLC purchased a new stake in Abeona Therapeutics in the 4th quarter worth $346,000. 62.04% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Abeona Therapeutics Inc (ABEO) Expected to Post Quarterly Sales of $270,000.00” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/abeona-therapeutics-inc-abeo-expected-to-post-quarterly-sales-of-270000-00.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.